New Marketing Agreement Provides ZymeTx Access to
National Physician Organization
Provider Select to Offer ZstatFlu Test to 41,000 Member Physicians in the U.S.
SAN DIEGO and OKLAHOMA CITY--(BW HealthWire)--Feb. 24, 2000-- Provider Select, an affiliate of Premier, Inc., is
adding ZymeTx, Inc.'s (Nasdaq:ZMTX - news) rapid point-of-care flu diagnostic test, ZstatFlu(TM), to its nationwide
physician program, Provider Select:MD.
Provider Select offers savings to facilities owned, managed by or affiliated with Premier member hospitals and health care
systems. The company represents over 41,000 physicians across the country.
``We are pleased to offer ZstatFlu to Provider Select members,' noted Norman Proulx, ZymeTx's President and CEO.
``ZstatFlu has become an invaluable tool in helping physicians appropriately treat their patients for influenza. The
availability of our product to Provider Select physician members exposes ZstatFlu to thousands of new physicians
nationwide.'
ZstatFlu is a 20-minute throat swab test administered in the doctor's office. The first test able to detect all strains of
Influenza A and B, ZstatFlu has emerged as the most widely used flu diagnostic test in the country, according to the company.
``The availability of new therapeutics for the treatment of influenza has elevated the importance of being able to obtain fast
and accurate flu diagnosis for patients with flu symptoms,' stated Joe Greskoviak, vice president of Provider Select.
``Offering our members access to contemporary solutions like ZstatFlu is a primary function of Provider Select.'
The new agreement is effective immediately.
About Provider Select
Provider Select is an operations improvement company dedicated to the non-acute care market. Backed by the purchasing
power of Premier, Provider Select:MD addresses the diverse and unique needs of the physician marketplace. Its
membership includes more than 13,000 practices representing over 41,000 physicians.
The program provides savings opportunities on a broad portfolio of products and services beyond traditional
medical/surgical supplies. These contracts include transcription services, office supplies, Internet claims processing and
magazine subscriptions. The Provider Select website can be accessed at www.providerselect.com.
About Premier, Inc.
Premier, Inc., one of the largest strategic alliances in the country, is owned by 217 health care systems which operate more
than 800 hospitals and are affiliated with more than 900 additional hospitals. Its group purchasing program serves
approximately 1,800 hospitals, several thousand physician practices, and other non-acute care sites. Collectively, these
providers purchase approximately $12 billion a year in pharmaceuticals, biomedical equipment and other supplies through
Premier group contracts. Premier's website can be accessed at www.premierinc.com.
About ZymeTx, Inc.
ZymeTx, Inc. is an emerging biotechnology company engaged in the development of unique products for the diagnosis and
treatment of viral diseases, viral management and disease surveillance. The Company developed ZstatFlu(TM) and the
National Flu Surveillance Network(TM) (NFSN), a network of more than 875 surveillance sites located throughout the
United States which allows physicians to track influenza in their communities. The NFSN, which can be accessed at
www.fluwatch.com, predicts and monitors regional influenza outbreaks through more than 4,000 physicians reporting
nationwide, allowing them to alert their patients and communities regarding the risks of influenza and the availability of
antiviral medications to ease the impact of the disease. ZstatFlu and the National Flu Surveillance Network are trademarks
of ZymeTx, Inc. Additional information on the Company and its services can be found on the Internet at www.zymetx.com,
www.fluwatch.com and www.flu101.com.
Safe Harbor Statement
This press release includes statements that may constitute ``forward-looking' statements, usually containing the words
``believe,' ``estimate,' ``project,' ``expect' or similar expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and
services in the marketplace, competitive factors, dependence upon third-party vendors, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this
release.
Contact:
ZymeTx, Inc.
Norman R. Proulx, CEO
G. Carl Gibson, CFO
405/271-1314
www.zymetx.com
or
Premier, Inc.
Laura Yandell, 704/733-5425 |
